Warburg Pincus completed the largest fundraise in its 57-year history as the firm’s flagship strategy attracted $17.3 billion.
Launched in 2021, Warburg Pincus Global Growth 14 is focused on creating a diverse, differentiated portfolio characterized by high-conviction theses and strong operating performance, officials added. The previous fund in the flagship series raised $15 billion in 2018.
Warburg Pincus CEO Chip Kaye said he was grateful for the investor support in one of the toughest-ever fundraising environments.
“Given that back-drop, we remain disciplined about investment pacing and prioritizing high conviction themes,” Kay said. “Additionally, geographic and sector diversification coupled with over five decades of investment experience fundamentally drives our consistency — especially in uncertain moments.”
New and existing investors include public and private pension funds, sovereign investors, insurance companies, endowments, foundations, fund of funds, family offices and high-net-worth individuals.
“This is a challenging period for investors, with rising rates and geopolitical tension, but also new promise from this wave of innovation,” said Timothy Geithner, chairman of Warburg Pincus, which has $83 billion in assets under management. “This puts a premium on diversification, a careful and disciplined approach to investing, and deep expertise on the shifting frontiers of technology, across sectors and economies. We look forward to continuing to navigate the ever-shifting mix of opportunities and challenges, partnering with excellent management teams to build great companies.”
One of firm’s distinguishing characteristics is ability to work collaboratively across distinct industry groups with deep domain expertise to identify new and emerging trends around the world, according to Jeff Perlman, president of Warburg Pincus. “We are excited about the current investment landscape and are looking forward to putting this capital to work as a partner of choice with innovative management teams across the globe,” he said.
To date, investments completed by the fund include Simtra BioPharma Solutions (formerly Baxter’s BioPharma Solutions business), Ensemble Health, EverBank, Internet Brands, Norstella, Oona Insurance, ParetoHealth, and Watertec India.
Kirkland & Ellis served as legal advisor for WPGG 14.
